Floatz logo

Itil-168

Cervical Cancer

Instil BioPhase 1Active
C
37/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
65/ 100

Competitive context

159 Active assets in the Cervical Cancer cohort.

Asset / SponsorPhaseRating
Vinorelbine
UNICANCER
Phase 2BBB
Indocyanine Green
Istanbul University
Phase 4BB
Tisotumab Vedotin
Seagen Inc.
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
Uganda Cancer Institute
Phase 3B
Carboplatin
Merck Sharp & Dohme LLC
Phase 3B

View all 50 →

Same molecule, other indications

Itil-168 is also rated in:

head and neck squamous cell carcinomaDormant
C
Indicative ·
37 / 100
View asset →
non-small cell lung carcinomaDormant
C
Indicative ·
36 / 100
View asset →
cutaneous melanomaDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →